Alik Magomedovich Rakhaev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alik Magomedovich Rakhaev has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Amina Magomedovna Alieva
Pirogov Russian National Research Medical University
15 shared publications - Igor Gennadievich Nikitin
N.I. Pirogov Russian National Research Medical University
14 shared publications - Irina E. Baykova
Pirogov Russian National Research Medical University
8 shared publications - Natalia Vadimovna Teplova
Pirogov Russian National Research Medical University
8 shared publications - Dzhannet Anuarovna Elmurzaeva
Kabardino-Balkarian State University
7 shared publications - Lidiya M. Shnakhova
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
5 shared publications
Latest Publications
- 15 May 2026
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (2) , 13-21
Matrix metalloproteinase 2 as a biological marker in heart failure
Heart failure (HF) is one of the major challenges in modern healthcare. Researches focused on new biological markers can significantly improve early detection and selection of effective therapeutic methods for patients with cardiovascular diseases (CVD). In recent years, matrix metalloproteinases (MMPs) are actively studied in cardiology. These proteolytic enzymes have stable structure. They are capable of breaking down peptide bonds in most extracellular matrix components. The objective of this review was to assess current experimental and clinical data on MMP-2 as a new diagnostic and prognostic marker in heart failure. MMP-2 is considered a key protease involved in heart remodeling. Elevated MMP-2 in the heart can lead to unfavorable ventricular remodeling and systolic heart dysfunction, even without other lesions. Clinical studies highlight significance of MMP-2 as a biomarker in diagnosis and prognosis of HF. Future research can provide more obvious data on feasibility of MMP-2 as a laboratory tool for diagnosing and assessing the risk in patients with HF. Further studies are also needed to explore the impact of MMP-2 inhibitors on morbidity and mortality in cardiovascular diseases.
- 15 May 2026
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (2) , 13-21
Matrix metalloproteinase 2 as a biological marker in heart failure
Heart failure (HF) is one of the major challenges in modern healthcare. Researches focused on new biological markers can significantly improve early detection and selection of effective therapeutic methods for patients with cardiovascular diseases (CVD). In recent years, matrix metalloproteinases (MMPs) are actively studied in cardiology. These proteolytic enzymes have stable structure. They are capable of breaking down peptide bonds in most extracellular matrix components. The objective of this review was to assess current experimental and clinical data on MMP-2 as a new diagnostic and prognostic marker in heart failure. MMP-2 is considered a key protease involved in heart remodeling. Elevated MMP-2 in the heart can lead to unfavorable ventricular remodeling and systolic heart dysfunction, even without other lesions. Clinical studies highlight significance of MMP-2 as a biomarker in diagnosis and prognosis of HF. Future research can provide more obvious data on feasibility of MMP-2 as a laboratory tool for diagnosing and assessing the risk in patients with HF. Further studies are also needed to explore the impact of MMP-2 inhibitors on morbidity and mortality in cardiovascular diseases.
- Open Access
- 22 September 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (3) , 250-262
Asprosin as a novel biological marker of atherosclerosis and carbohydrate metabolism disorders
Cardiovascular diseases represent a major global medical, social, and economic challenge. Active research is being conducted to identify new biological markers and therapeutic targets to develop effective approaches for risk stratification and secondary prevention of cardiovascular diseases. Despite the identification of numerous cardiovascular biomarkers, their translation into clinical practice has largely been unsuccessful. Recently, researchers have increasingly focused on asprosin. The primary objective of this article is to analyze existing studies on the role of asprosin as a biomarker in atherosclerosis and carbohydrate metabolism disorders. An increasing body of experimental evidence indicates that this biomarker contributes to the development and progression of atherosclerosis, diabetes mellitus, obesity, and polycystic ovary syndrome. Asprosin regulates various physiological processes, including appetite stimulation, glucose release, insulin secretion, apoptosis, and inflammation. Based on available clinical data, asprosin appears to be a promising molecule with both diagnostic and prognostic value in the context of atherosclerosis and carbohydrate metabolism disorders. Further research is needed to explore asprosin as an additional laboratory biomarker. Modulation of asprosin concentration and expression may become a promising therapeutic strategy for patients with atherosclerosis and carbohydrate metabolism disorders.
- 22 September 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (3) , 250-262
Open AccessAsprosin as a novel biological marker of atherosclerosis and carbohydrate metabolism disorders
Cardiovascular diseases represent a major global medical, social, and economic challenge. Active research is being conducted to identify new biological markers and therapeutic targets to develop effective approaches for risk stratification and secondary prevention of cardiovascular diseases. Despite the identification of numerous cardiovascular biomarkers, their translation into clinical practice has largely been unsuccessful. Recently, researchers have increasingly focused on asprosin. The primary objective of this article is to analyze existing studies on the role of asprosin as a biomarker in atherosclerosis and carbohydrate metabolism disorders. An increasing body of experimental evidence indicates that this biomarker contributes to the development and progression of atherosclerosis, diabetes mellitus, obesity, and polycystic ovary syndrome. Asprosin regulates various physiological processes, including appetite stimulation, glucose release, insulin secretion, apoptosis, and inflammation. Based on available clinical data, asprosin appears to be a promising molecule with both diagnostic and prognostic value in the context of atherosclerosis and carbohydrate metabolism disorders. Further research is needed to explore asprosin as an additional laboratory biomarker. Modulation of asprosin concentration and expression may become a promising therapeutic strategy for patients with atherosclerosis and carbohydrate metabolism disorders.
- Open Access
- 24 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 291-300
Myokines as biological markers in disorders of carbohydrate metabolism and atherosclerosis
Cardiovascular diseases cause more than half of all deaths. Coronary heart disease is the leading cause of death worldwide. The main factor contributing to the development of coronary heart disease is atherosclerosis, which often does not show symptoms in the early stages. Carbohydrate metabolism disorders play an important role in the occurrence and worsening of cardiovascular diseases. The search for cardiovascular biomarkers that could help in the diagnosis of cardiovascular diseases and serve as prognostic indicators continues. This scientific review focuses on the importance of assessing myokines. To date, the significance of such myokines as myostatin, irisin, meteorin-like protein, brain-derived neurotrophic factor, apelin, mitsugumin 53 and others in cardiovascular pathology has been demonstrated. It has been established that myostatin negatively affects carbohydrate metabolism and atherosclerotic processes, worsening the lipid profile, increasing the accumulation of adipose tissue and reducing its “browning”. Suppression of myostatin in myocardial infarction promotes cardiac recovery; its concentrations, along with the level of troponin, reflect myocardial damage. Studies of the brain-derived neurotrophic factor also emphasize the importance and feasibility of its determination in diabetes mellitus and ischemic heart disease. Evaluation of the level of meteorin-like protein can be useful in diabetes mellitus and assessing the risk of atherosclerosis. A reliable relationship has been established between apelin and irisin with carbohydrate metabolism disorders and atherosclerotic cardiovascular diseases, which also makes them promising therapeutic molecules. Mitsugumin 53 has shown relevance as a marker in atherosclerosis, but its effect on carbohydrate metabolism requires clarification. Serial myokine testing, including the use of multimarker panels, requires further study to confirm its relevance in clinical practice.
- 24 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 291-300
Open AccessMyokines as biological markers in disorders of carbohydrate metabolism and atherosclerosis
Cardiovascular diseases cause more than half of all deaths. Coronary heart disease is the leading cause of death worldwide. The main factor contributing to the development of coronary heart disease is atherosclerosis, which often does not show symptoms in the early stages. Carbohydrate metabolism disorders play an important role in the occurrence and worsening of cardiovascular diseases. The search for cardiovascular biomarkers that could help in the diagnosis of cardiovascular diseases and serve as prognostic indicators continues. This scientific review focuses on the importance of assessing myokines. To date, the significance of such myokines as myostatin, irisin, meteorin-like protein, brain-derived neurotrophic factor, apelin, mitsugumin 53 and others in cardiovascular pathology has been demonstrated. It has been established that myostatin negatively affects carbohydrate metabolism and atherosclerotic processes, worsening the lipid profile, increasing the accumulation of adipose tissue and reducing its “browning”. Suppression of myostatin in myocardial infarction promotes cardiac recovery; its concentrations, along with the level of troponin, reflect myocardial damage. Studies of the brain-derived neurotrophic factor also emphasize the importance and feasibility of its determination in diabetes mellitus and ischemic heart disease. Evaluation of the level of meteorin-like protein can be useful in diabetes mellitus and assessing the risk of atherosclerosis. A reliable relationship has been established between apelin and irisin with carbohydrate metabolism disorders and atherosclerotic cardiovascular diseases, which also makes them promising therapeutic molecules. Mitsugumin 53 has shown relevance as a marker in atherosclerosis, but its effect on carbohydrate metabolism requires clarification. Serial myokine testing, including the use of multimarker panels, requires further study to confirm its relevance in clinical practice.
- 17 February 2025
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 31 (1) , 39-50
The role of matrix metalloproteinase 9 as a biological marker in heart failure
Heart failure (HF) is an important medical, social and economic problem. The study of new biological markers deepens our understanding of the pathogenesis of this disease. In modern cardiology, there is a growing interest in matrix metalloproteinases (MMPs). These enzymes play an important role in tissue remodeling, angiogenesis, as well as in cell proliferation, migration and differentiation. The purpose of this literature review is to analyze current experimental and clinical data on MMP-9 as a new diagnostic and prognostic marker in HF. This review presents an analysis of modern publications on a given topic. We conducted an analysis of literature sources covering all important materials as of 01.12.2024. Experimental studies have established that MMP-9 is a key participant in cardiac remodeling, since it is directly involved in the degradation of extracellular matrix proteins and the activation of profibrotic pathways, as well as cytokines and chemokines. Clinical trial data indicate the significant importance of MMP-9 for diagnosis and prognosis in patients with HF.
- 17 February 2025
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 31 (1) , 39-50
The role of matrix metalloproteinase 9 as a biological marker in heart failure
Heart failure (HF) is an important medical, social and economic problem. The study of new biological markers deepens our understanding of the pathogenesis of this disease. In modern cardiology, there is a growing interest in matrix metalloproteinases (MMPs). These enzymes play an important role in tissue remodeling, angiogenesis, as well as in cell proliferation, migration and differentiation. The purpose of this literature review is to analyze current experimental and clinical data on MMP-9 as a new diagnostic and prognostic marker in HF. This review presents an analysis of modern publications on a given topic. We conducted an analysis of literature sources covering all important materials as of 01.12.2024. Experimental studies have established that MMP-9 is a key participant in cardiac remodeling, since it is directly involved in the degradation of extracellular matrix proteins and the activation of profibrotic pathways, as well as cytokines and chemokines. Clinical trial data indicate the significant importance of MMP-9 for diagnosis and prognosis in patients with HF.
- Open Access
- 15 November 2024
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 15 (3) , 221-230
Prospects of using miRNA-378 as a biomarker for cardiovascular diseases: A literature review
Currently, there is an active search for new biomarkers and therapeutic targets to develop effective approaches to risk stratification and secondary prevention of cardiovascular diseases (CVD). Microribonucleic acids (miRNAs) are of particular interest to investigators. MiRNAs are endogenous small noncoding RNAs that regulate the transcription of factors that play a role in the proliferation, differentiation, cell growth, and tissue remodeling processes in CVD. MiRNA-378 is currently being analyzed as a biomarker for CVD. Thus, in this review, we aimed to describe the regulatory role of miRNA-378 and provide strong evidence for its feasibility as a biomarker. Further preclinical and clinical studies are required to identify the potential benefits of miRNA-378 as a biomarker in CVD.
- 15 November 2024
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 15 (3) , 221-230
Open AccessProspects of using miRNA-378 as a biomarker for cardiovascular diseases: A literature review
Currently, there is an active search for new biomarkers and therapeutic targets to develop effective approaches to risk stratification and secondary prevention of cardiovascular diseases (CVD). Microribonucleic acids (miRNAs) are of particular interest to investigators. MiRNAs are endogenous small noncoding RNAs that regulate the transcription of factors that play a role in the proliferation, differentiation, cell growth, and tissue remodeling processes in CVD. MiRNA-378 is currently being analyzed as a biomarker for CVD. Thus, in this review, we aimed to describe the regulatory role of miRNA-378 and provide strong evidence for its feasibility as a biomarker. Further preclinical and clinical studies are required to identify the potential benefits of miRNA-378 as a biomarker in CVD.
- 14 March 2024
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 30 (1) , 48-66
Diagnostic, prognostic and therapeutic aspects of apelin in cardiovascular diseases
Biological markers have been thoroughly incorporated into clinical practice as a convenient and simple method for diagnosing and monitoring the condition of patients. The analysis of biomarkers has found its niche in oncology; however, their application in cardiovascular diseases is still in its infancy. Studies on apelin indicate the potential diagnostic and prognostic significance of the assessment of this marker in patients with cardiovascular diseases. The beneficial effect of apelin on the heart and blood vessels allows us to consider this marker as a therapeutic target. The combination of apelin with other biological markers, particularly brain natriuretic peptide and its precursor, may increase the predictive value of apelin.
- 14 March 2024
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 30 (1) , 48-66
Diagnostic, prognostic and therapeutic aspects of apelin in cardiovascular diseases
Biological markers have been thoroughly incorporated into clinical practice as a convenient and simple method for diagnosing and monitoring the condition of patients. The analysis of biomarkers has found its niche in oncology; however, their application in cardiovascular diseases is still in its infancy. Studies on apelin indicate the potential diagnostic and prognostic significance of the assessment of this marker in patients with cardiovascular diseases. The beneficial effect of apelin on the heart and blood vessels allows us to consider this marker as a therapeutic target. The combination of apelin with other biological markers, particularly brain natriuretic peptide and its precursor, may increase the predictive value of apelin.
- Open Access
- 20 December 2023
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 14 (4) , 257-268
Salusin-α and salusin-β as new biological markers in cardiovascular diseases: literature review
Despite significant advances in medicine, cardiovascular disease continues to be the leading cause of death worldwide. An important task in cardiology is the search and study of new cardiovascular biological markers. In recent years, salusins have attracted the interest of scientists. Salusins are endogenous biologically active peptides, which were first identified in 2003. Thus far, studies have demonstrated that salusin-α and salusin-β play important roles in vascular remodeling, inflammation, hypertension, and atherosclerotic processes. Salusin-α exhibits an antiatherogenic effect, whereas salusin-β plays a proatherogenic role. Despite the diverse biological, physiological, and pathophysiological aspects of salusins, the exact mechanism of their cardiovascular effects is not fully known. Further in-depth studies of the role of salusins in cardiovascular diseases are required. The regulation of the concentration and expression of salusin-α and salusin-β may prove to be a promising strategy for the treatment of patients with cardiac diseases.
- 20 December 2023
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 14 (4) , 257-268
Open AccessSalusin-α and salusin-β as new biological markers in cardiovascular diseases: literature review
Despite significant advances in medicine, cardiovascular disease continues to be the leading cause of death worldwide. An important task in cardiology is the search and study of new cardiovascular biological markers. In recent years, salusins have attracted the interest of scientists. Salusins are endogenous biologically active peptides, which were first identified in 2003. Thus far, studies have demonstrated that salusin-α and salusin-β play important roles in vascular remodeling, inflammation, hypertension, and atherosclerotic processes. Salusin-α exhibits an antiatherogenic effect, whereas salusin-β plays a proatherogenic role. Despite the diverse biological, physiological, and pathophysiological aspects of salusins, the exact mechanism of their cardiovascular effects is not fully known. Further in-depth studies of the role of salusins in cardiovascular diseases are required. The regulation of the concentration and expression of salusin-α and salusin-β may prove to be a promising strategy for the treatment of patients with cardiac diseases.
- Open Access
- 15 October 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (10) , 668-673
The role of interleukin-27 in atherosclerotic cardiovascular diseases: A review
The main cause of many cardiovascular diseases is atherosclerosis. The atherosclerotic process, manifested by acute vascular accidents, such as myocardial and/or cerebral infarction, or chronic ischemic conditions, such as coronary heart disease and cerebrovascular disease, is essentially a systemic inflammatory process. The significant role of T-cells, macrophages, neutrophils and cytokines in this pathological process has been proven. The presented literature review indicates the potentially important diagnostic and prognostic value of the interleukin-27 assessment. It is expected that further scientific and clinical studies will demonstrate the possibility of using this cytokine as an additional laboratory tool for the diagnosis, risk stratification and prediction of cardiovascular events in patients with a cardiac profile.
- 15 October 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (10) , 668-673
Open AccessThe role of interleukin-27 in atherosclerotic cardiovascular diseases: A review
The main cause of many cardiovascular diseases is atherosclerosis. The atherosclerotic process, manifested by acute vascular accidents, such as myocardial and/or cerebral infarction, or chronic ischemic conditions, such as coronary heart disease and cerebrovascular disease, is essentially a systemic inflammatory process. The significant role of T-cells, macrophages, neutrophils and cytokines in this pathological process has been proven. The presented literature review indicates the potentially important diagnostic and prognostic value of the interleukin-27 assessment. It is expected that further scientific and clinical studies will demonstrate the possibility of using this cytokine as an additional laboratory tool for the diagnosis, risk stratification and prediction of cardiovascular events in patients with a cardiac profile.
- 10 October 2022
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 28 (4) , 291-304
Interleukin-13 and cardiovascular diseases: literature review
Cardiovascular diseases remain the leading cause of death worldwide despite significant advances in medicine and increased life expectancy. It is very important to search for and study new cardiovascular biological markers that can help the early diagnosis of cardiovascular diseases, serve as a laboratory tool for assessing the effectiveness of treatment, be a predictive marker of possible adverse clinical outcomes, and be a significant criterion for risk stratification. This review aims to consider interleukin-13 (IL-13) as a diagnostic and prognostic biomarker in cardiovascular pathology. IL-13 is involved in the development of many cardiovascular diseases, according to variousin vitroandin vivostudies, but its role remains unclear until the end. IL-13 has a positive effect, promoting the development of the heart at an early stage and facilitating the recovery of the heart after a myocardial infarction. Due to the induction of fibrosis and adverse cardiac remodeling, long-term IL-13 synthesis appears to be a risk factor for adverse outcomes in chronic cardiovascular diseases, such as heart failure. Understanding the effect of IL-13 on cardiac metabolism will shed light on possible new pathogenetic mechanisms for the development of heart disease. As a rule, an increase in the level of IL-13 in the blood serum goes in parallel with its expression in the tissues of the heart. However, the dissociation of systemic inflammatory reactions and local expression is not excluded. The introduction of IL-13 can restore the regenerative capacity of cardiomyocytes and reduce cardiac dysfunction. IL-13 deficiency limits the proliferation of cardiomyocytes, induces compensatory hypertrophy of cardiomyocytesin vitroand deletion of IL-13, leads to cardiac dysplasia, and impairs recovery processesin vivo. Although IL-13 is associated with cardiac fibrosis, cardiomyocyte proliferation, myocardial hypertrophy, immune cell recruitment and differentiation, and chemokine secretion in the heart, it is precise signaling pathways and underlying mechanisms of action remain poorly understood.
- 10 October 2022
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 28 (4) , 291-304
Interleukin-13 and cardiovascular diseases: literature review
Cardiovascular diseases remain the leading cause of death worldwide despite significant advances in medicine and increased life expectancy. It is very important to search for and study new cardiovascular biological markers that can help the early diagnosis of cardiovascular diseases, serve as a laboratory tool for assessing the effectiveness of treatment, be a predictive marker of possible adverse clinical outcomes, and be a significant criterion for risk stratification. This review aims to consider interleukin-13 (IL-13) as a diagnostic and prognostic biomarker in cardiovascular pathology. IL-13 is involved in the development of many cardiovascular diseases, according to variousin vitroandin vivostudies, but its role remains unclear until the end. IL-13 has a positive effect, promoting the development of the heart at an early stage and facilitating the recovery of the heart after a myocardial infarction. Due to the induction of fibrosis and adverse cardiac remodeling, long-term IL-13 synthesis appears to be a risk factor for adverse outcomes in chronic cardiovascular diseases, such as heart failure. Understanding the effect of IL-13 on cardiac metabolism will shed light on possible new pathogenetic mechanisms for the development of heart disease. As a rule, an increase in the level of IL-13 in the blood serum goes in parallel with its expression in the tissues of the heart. However, the dissociation of systemic inflammatory reactions and local expression is not excluded. The introduction of IL-13 can restore the regenerative capacity of cardiomyocytes and reduce cardiac dysfunction. IL-13 deficiency limits the proliferation of cardiomyocytes, induces compensatory hypertrophy of cardiomyocytesin vitroand deletion of IL-13, leads to cardiac dysplasia, and impairs recovery processesin vivo. Although IL-13 is associated with cardiac fibrosis, cardiomyocyte proliferation, myocardial hypertrophy, immune cell recruitment and differentiation, and chemokine secretion in the heart, it is precise signaling pathways and underlying mechanisms of action remain poorly understood.
- Open Access
- 29 August 2022
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 28 (3) , 201-214
Interleukin-18 and cardiovascular diseases: a literature review
Cardiovascular disease is a serious problem of modern healthcare, which is one of the leading causes of general mortality, reduction and loss of ability to work, as well as disability. The search and the study of new cardiovascular biological markers can allow the optimization of the diagnosis of cardiovascular diseases, development of laboratory tools for assessing the effectiveness of a treatment, and improving the prediction of possible adverse clinical outcomes. The purpose of this review was to promote the consideration of interleukin-18 (IL-18) as a diagnostic and prognostic marker in cardiovascular pathology. For the first time, K. Nakamura et al. in 1989, described IL-18 and interferon-gamma (IFN--inducing factor, IFN--inducing factor, IGIF) as a new, previously unknown factor that induces the production of IFN-. Data obtained from rodent models and clinical studies have demonstrated that IL-18 is involved in the pathogenesis of several diseases, immune-inflammatory rheumatic conditions, systemic vasculitis, cardiovascular diseases, malignancy, central nervous system pathologies, inflammatory bowel disease, psoriasis, and diseases of the kidneys and lungs. In animal models of acute myocardial infarction, pressure overload, and left ventricular dysfunction, IL-18 has been demonstrated to increase cardiomyocyte hypertrophy, induce cardiac contractile dysfunction, and extracellular matrix remodeling. It is therefore expected that further scientific and clinical studies can demonstrate the possibility of using IL-18 as an additional laboratory tool for the diagnosis, risk stratification, and prediction of cardiovascular events in patients with a cardiac profile. The effect of blockade of this cytokine on reducing morbidity and mortality in patients with cardiovascular diseases remains to be assessed for more detail, while considering reasonable economic costs and the side effects of drugs.
- 29 August 2022
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 28 (3) , 201-214
Open AccessInterleukin-18 and cardiovascular diseases: a literature review
Cardiovascular disease is a serious problem of modern healthcare, which is one of the leading causes of general mortality, reduction and loss of ability to work, as well as disability. The search and the study of new cardiovascular biological markers can allow the optimization of the diagnosis of cardiovascular diseases, development of laboratory tools for assessing the effectiveness of a treatment, and improving the prediction of possible adverse clinical outcomes. The purpose of this review was to promote the consideration of interleukin-18 (IL-18) as a diagnostic and prognostic marker in cardiovascular pathology. For the first time, K. Nakamura et al. in 1989, described IL-18 and interferon-gamma (IFN--inducing factor, IFN--inducing factor, IGIF) as a new, previously unknown factor that induces the production of IFN-. Data obtained from rodent models and clinical studies have demonstrated that IL-18 is involved in the pathogenesis of several diseases, immune-inflammatory rheumatic conditions, systemic vasculitis, cardiovascular diseases, malignancy, central nervous system pathologies, inflammatory bowel disease, psoriasis, and diseases of the kidneys and lungs. In animal models of acute myocardial infarction, pressure overload, and left ventricular dysfunction, IL-18 has been demonstrated to increase cardiomyocyte hypertrophy, induce cardiac contractile dysfunction, and extracellular matrix remodeling. It is therefore expected that further scientific and clinical studies can demonstrate the possibility of using IL-18 as an additional laboratory tool for the diagnosis, risk stratification, and prediction of cardiovascular events in patients with a cardiac profile. The effect of blockade of this cytokine on reducing morbidity and mortality in patients with cardiovascular diseases remains to be assessed for more detail, while considering reasonable economic costs and the side effects of drugs.